ERS Genomics: John Milad

ERS Genomics, which provides licensing to CRISPR/Cas9 technologies for commercial use, has appointed John Milad as its CEO. Milad was previously CEO of Quanta Dialysis Technologies. Prior to this, he was CFO of Nitec Pharma. He also has experience as a venture investor, with previous roles as partner and co-head of healthcare ventures at Downing, and investment director at NBGI Ventures. He has also held positions at Atlas Venture and Kirkland Investors. Milad also currently serves on the board of Kidney Research UK and Otivio.